Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth B Norton

Showing results (1-10 of 52) with videos related to

Pageof 6
Sort By:
Journal of Diabetes and Its Complications|January 18, 2019
Altered responses to pneumococcal vaccination in an elderly diabetic Japanese vaccine trial: The risk of concurrent vaccination strategiesElizabeth B Norton
Current Opinion in Immunology|November 17, 2023
Recent advances in enterotoxin vaccine adjuvantsJessica W Crothers, Elizabeth B Norton
Msphere|July 27, 2018
The Mucosal Vaccine Adjuvant LT(R192G/L211A) or dmLTJohn D Clements, Elizabeth B Norton
Current Opinion in Immunology|April 23, 2011
Defending the mucosa: adjuvant and carrier formulations for mucosal immunityLouise B Lawson, Elizabeth B Norton, John D Clements
Plos One|August 26, 2015
Evaluating the A-Subunit of the Heat-Labile Toxin (LT) As an Immunogen and a Protective Antigen Against Enterotoxigenic Escherichia coli (ETEC)Elizabeth B Norton, Luis M Branco, John D Clements
The Journal of Clinical Investigation|May 11, 2021
What should define a SARS-CoV-2 "breakthrough" infection?John S Schieffelin, Elizabeth B Norton, Jay K Kolls
Vaccine|January 19, 2023
Identifying a stable bulk dmLT adjuvant formulation at a clinically relevant concentrationMarcus R Estrada, Anan Bzami, Elizabeth B Norton, et al.
Plos One|January 14, 2020
LTA1 and dmLT enterotoxin-based proteins activate antigen-presenting cells independent of PKA and despite distinct cell entry mechanismsEduardo Valli, Robin L Baudier, Amanda J Harriett, et al.
Journal of Virology|January 8, 2010
Prophylactic administration of bacterially derived immunomodulators improves the outcome of influenza virus infection in a murine modelElizabeth B Norton, John D Clements, Thomas G Voss, et al.
Clinical and Vaccine Immunology : CVI|February 4, 2011
Characterization of a mutant Escherichia coli heat-labile toxin, LT(R192G/L211A), as a safe and effective oral adjuvantElizabeth B Norton, Louise B Lawson, Lucy C Freytag, et al.
Pageof 6

Showing results (1-10 of 52) with videos related to

Sort By:
Pageof 6
Journal of Diabetes and Its Complications|January 18, 2019
Altered responses to pneumococcal vaccination in an elderly diabetic Japanese vaccine trial: The risk of concurrent vaccination strategiesElizabeth B Norton
Current Opinion in Immunology|November 17, 2023
Recent advances in enterotoxin vaccine adjuvantsJessica W Crothers, Elizabeth B Norton
Msphere|July 27, 2018
The Mucosal Vaccine Adjuvant LT(R192G/L211A) or dmLTJohn D Clements, Elizabeth B Norton
Current Opinion in Immunology|April 23, 2011
Defending the mucosa: adjuvant and carrier formulations for mucosal immunityLouise B Lawson, Elizabeth B Norton, John D Clements
Plos One|August 26, 2015
Evaluating the A-Subunit of the Heat-Labile Toxin (LT) As an Immunogen and a Protective Antigen Against Enterotoxigenic Escherichia coli (ETEC)Elizabeth B Norton, Luis M Branco, John D Clements
The Journal of Clinical Investigation|May 11, 2021
What should define a SARS-CoV-2 "breakthrough" infection?John S Schieffelin, Elizabeth B Norton, Jay K Kolls
Vaccine|January 19, 2023
Identifying a stable bulk dmLT adjuvant formulation at a clinically relevant concentrationMarcus R Estrada, Anan Bzami, Elizabeth B Norton, et al.
Plos One|January 14, 2020
LTA1 and dmLT enterotoxin-based proteins activate antigen-presenting cells independent of PKA and despite distinct cell entry mechanismsEduardo Valli, Robin L Baudier, Amanda J Harriett, et al.
Journal of Virology|January 8, 2010
Prophylactic administration of bacterially derived immunomodulators improves the outcome of influenza virus infection in a murine modelElizabeth B Norton, John D Clements, Thomas G Voss, et al.
Clinical and Vaccine Immunology : CVI|February 4, 2011
Characterization of a mutant Escherichia coli heat-labile toxin, LT(R192G/L211A), as a safe and effective oral adjuvantElizabeth B Norton, Louise B Lawson, Lucy C Freytag, et al.
Pageof 6